IJU this issue

Abstract

Thank you for reading this issue of IJU. This issue contains two Review Articles, 12 Original Articles, one Short Communication and one Case Report – rich in variety. One of the Review Articles was written by Lee-Ying et al. (Alberta, Canada) on current management and future perspectives of metastatic renal cell carcinoma. We have a many treatment tools against metastatic renal cell carcinoma, such as immunotherapy, vascular endothelial growth factor inhibition and mammalian target of rapamycin inhibition. This article reviews the major treatment advances that have occurred for metastatic renal cell cancer with the advent of targeted treatments, summarizes the evidence to support their use and addresses clinical issues that have arisen with them. To help guide clinicians in their decision-making with these emerging therapeutic choices, the evidence for sequencing and combining these agents, and the need for biomarkers will be addressed. The role of surgical management options, such as cytoreductive nephrectomy and metastectomy, in the era of targeted treatment is also reviewed. The other Review Article was written by Shimizu et al. (Kochi, Japan) on the lower urinary tract symptoms related to vascular dysfunction. Lower urinary tract symptoms, benign prostatic hyperplasia/benign prostatic enlargement and erectile dysfunction are common conditions in elderly men, and the prevalence of these disorders increases with aging in men. This article reviews the relationship between decreased pelvic blood flow and lower urinary tract symptoms, benign prostatic hyperplasia/benign prostatic enlargement, and erectile dysfunction. Furthermore, they suggest possible common mechanisms underlining these urological conditions. This issue contains two Original Articles on premature ejaculation. Kirecci et al. (Istanbul, Turkey) report the relationship between plasma melatonin levels and the efficacy of selective serotonin reuptake inhibitors treatment on premature ejaculation. Shi et al. (Guangdong, China) report on resiniferatoxin for treatment of lifelong premature ejaculation. None declared.